30 results about "Hormaomycin" patented technology

An abscisic acid (1) is a plant hormone widely existing in a plant and has important physiological function, however, the application range is limited by the high-speed photo-isomerization characteristics. A bioisosteres cis 2, 3-cyclopropanated abscisic acid analogue of the abscisic acid is compounded through 2, 3-cyclopropanation, and the photostability is four times as that of the abscisic acid.

The invention provides a method for screening a I type 17 beta-hydroxysteroid dehydrogenase inhibitor through an immobilized enzyme, and belongs to the technical field of enzymology and enzyme engineering. I type 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD1) has the important function in treating hormone-dependent diseases. At present, a substrate radiolabelling method is mainly adopted in studying the activity of 17 beta-HSD1, due to the fact that the free enzyme of 17 beta-HSD1 is likely to be inactivated, 17 beta-HSD1 is hard to prepare, a fresh placenta is needed for preparing an enzyme source in a new medicine screening experiment of every time, raw materials are hard to obtain, the price is high, and difficulty is brought to the screening work of new medicine. According to the method, an amino-modified silicon ball is adopted as a carrier, a glutaraldehyde crosslinking method is utilized, 17 beta-HSD1 extracted from the placenta is fixed, an external immobilization 17 beta-HSD1 enzyme model is built, androstenedione is adopted as a substrate, a high performance liquid chromatography method is used for detecting products, and the potential 17 beta-HSD1 inhibitor is screened. According to the method, instability of the free enzyme is overcome, operation is easy, the manufacturing cost is low, and repeated using is achieved.

The invention relates to a naphthlamide derivative used as a protein kinase inhibitor and a histone deacetylase inhibitor. The structure of the naphthlamide derivative is as shown as a formula I, wherein a position 7 is provided with substituent groups R which include F, Cl, Br, I, OCH3 and other substituent groups as shown in the accompanying drawings, and the names of the substituent groups arefluorine, chlorine, bromine, iodine, methoxyl, 4-morpholinyl ethyoxyl, 4-morpholinyl methyl phenyl, acryloyl amino and 2-beuteamide. The naphthlamide derivative used as the protein kinase inhibitor and the histone deacetylase inhibitor can be used for curing cardiovascular diseases, metabolic diseases, allergy, cancers and hormone-related diseases. The invention additionally provides a synthesis method of the compound. The method has the advantages that the raw materials are easy to obtain, the method is simple to operate and the method is suitable for large-scale industrial production.

The invention provides a preparation method of natamycin produced by fermentation regulation of Streptomyces gilvosporeus and relates to the technical field of bioengineering. The method comprises steps as follows: strain activation, primary seed culture and shake flask fermentation, wherein the strain is Streptomyces gilvosporeus, ATCC 13326. The influence of three different plant hormones including IAA, GA and 6-BA, as well as precursor substance sodium propionate added in a fermentation process in a compounding manner on Streptomyces gilvosporeus cell growth and natamycin synthesis are investigated in order to understand the regulating effect of the plant hormones and the precursor substance on Streptomyces gilvosporeus cell growth and natamycin synthesis, and experimental evidence is provided for improving the efficiency of Streptomyces gilvosporeus fermentation based natamycin production by the plant hormones and the precursor substance.

The invention provides a method for synthesizing an intermediate of a 17-bit hydroxyl acylated cortical hormone steroid medicament. The intermediate compound has a structural formula shown in the specification; 17-steroid carboxylic ester has a structural formula shown in the specification; and according to the method, a 17-bit ester group protected product is obtained by reducing an acid ester open loop under the catalysis of a gluconic acid aqueous solution. By adopting the method, a hydrolysis reaction is carried out by using the recyclable gluconic acid aqueous solution for catalysis, so that the use of organic solvent and reagents is effectively reduced, the cost is reduced, pollution is reduced, and the synthesis process is simplified.

A cDNA clone (HEV1) encoding hevein was isolated via polymerase chain reaction (PCR) using mixed oligonucleotides corresponding to two regions of hevein as primers and a Hevea brasiliensis latex cDNA library as a template. HEV1 is 1018 nucleotides long and includes an open reading frame of 204 amino acids. The deduced amino acid sequence contains a putative signal sequence of 17 amino acid residues followed by a 187 amino acid polypeptide. The amino-terminal region (43 amino acids) is identical to hevein and shows homology to several chitin-binding proteins and to the amino-termini of wound-induced genes in potato and poplar. The carboxyl-terminal portion of the polypeptide (144 amino acids) is 74-79% homologous to the carboxyl-terminal region of wound-inducible genes of potato. Wounding, as well as application of the plant hormones abscisic acid and ethylene, resulted in accumulation of hevein transcripts in leaves, stems and latex, but not in roots, as shown by using the cDNA as a probe. A fusion protein was produced in E. coli from the protein of the present invention and maltose binding protein produced by the E. coli.

The invention describes a retro-inverso (RI) gonadotropin-releasing hormone (GnRH) peptide which is capable of eliciting an immune response directed against GnRH, the peptide having the amino acid sequence GPRLGYSWHX, wherein the amino acids are D-amino acids and X is any amino acid. More particularly, X is E, Q, P or G, and even more particularly, X is E or Q. Thus, a preferred amino acid sequence for the peptide is GPRLGYSWHE. The peptide may optionally include one or more additional D-amino acids at its N- or C-terminus, for example a cysteine residue or a series of linker amino acids, such as a plurality of glycine amino acid residues. Thus, a second preferred amino acid sequence for the peptide is GPRLGYSWHEC, which includes a cysteine residue at the C-terminus for conjugation purposes. The invention also describes a vaccine composition for use in controlling fertility, heat, contraception and/or treating sex hormone-related diseases, and a method for controlling and or treating fertility and sex hormone-related diseases.

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

The inventors have discovered that substituting amino acid residues at positions 5 and/or 7 and/or 8 of the GnRH I (gonadotropin-releasing hormone) peptide sequence, and particularly removal of the arginine residue at position 8, results in elevated antiproliferative activitey. Furthermore, the introduction of certain D-amino acid residues at position 6 of the GnRH II peptide sequence results in elevated antiproliferative activity. This surprising discovery provides potent and selective agents for use in treating antiproliferative disorders, such as cancer.

The invention discloses a method for synthesizing an artificial antigen of progesterone, belonging to the technical field of biochemical industry. Specific hydroxyl on a progesterone analogue 17alpha-methyl-17beta-hydroxy steroid-4-alkene-3-ketone is utilized as a reaction group, and reacts with a 2-bromoacetic acid to obtain a progesterone hapten; and the hapten is connected with carrier protein bull serum albumin (BSA) to synthesize the artificial antigen of the progesterone by adopting a mixed anhydride method or the hapten is connected with carrier protein OVA to synthesize a coating antigen. The artificial antigen of the progesterone is successfully synthesized by the method; the synthesis process is simple; a plurality of parts with the same steroid hormone ring structures are fully exposed by the synthesis product; a group-selectivity progesterone monoclonal antibody can be obtained when the method is applied to immunoassay; and the national requirements of multiplex detection on progestational hormone are met.

The present invention relates to a conjugate of the formula P-L-I, wherein P is a peptide hormone effecting the metabolism of carbohydrates in vivo, L is a hydrolysable linker molecule consisting of L_p and L_i, and I is a molecule capable of inhibiting the effect of the peptide hormone P on the metabolism of carbohydrates in vivo. Under in vivo conditions, the conjugate is the major compound. When the concentration of glucose increases in vivo, the concentration of the peptide hormone effecting the metabolism of carbohydrates in vivo also increases.

Compositions and methods are described for making and using transgenic plants and plant parts having at least one auxotrophic requirement for an essential compound such as an amino acid, carbohydrate, fatty acid, nucleic acid, vitamin, plant hormone, or precursor thereof. Transgenic plants and plants parts having at least one auxotrophic requirement can be effectively biocontained by withdrawal of the essential compound.

The invention relates to four recombinant human corticotropin (ACTH) precursor proteins having an effect of increasing glucocorticoid levels in serum: ProACTH113, ProACTH72, ProACTH80, ProACTH141, anda method for preparing these four precursor proteins. ProACTH113 contains the 105th to 217th amino acid polypeptide chain of Pro-opiomelanocortin (POMC), ProACTH72 contains the 105th to 176th amino acid polypeptide chain of POMC, ProACTH80 contains the 138th and 217th amino acid polypeptide chains of POMC, and ProACTH141 contains the 77th to 217th amino acid polypeptide chains of POMC; all of thefour ACTH precursor proteins comprise amino acid sequences 1 to 39 of the ACTH polypeptide. For purification, the N-terminus of the four precursor proteins, ProACTH113, ProACTH72, ProACTH80, and ProACTH141, are linked to an enterokinase substrate sequence (EKst), and excess peptide sections connected with the N-terminus of the four precursor proteins are excised in vitro using histone-linked enterokinase. The free ProACTH113, ProACTH72, ProACTH80, and ProACTH141 are generated, and the histone-linked enterokinase is removed using a nickel column.

Novel Saccharomyces Cerevisiae mutant strains are provided for producing human parathyroid hormone. The novel strains acre genetically disrupted in at least one of the genes encoding the yapsin family of proteases Yapsin 1, Yapsin 2 and Yapsin 3 and harbor a human parathyroid hormone gene in their genomes. Culturing the novel strains results in the secretion of intact hPTH into culture media at high yield.